American Association for Cancer Research Annual Meeting 2022
Meet MILabs at the AACR
April 10-13, New Orleans (booth # 3915)
Advanced oncology imaging:
from basic research to precision radiotherapy
MILabs’ synergistic imaging approach visualizes everything oncology models have to show you. From rapid phenotyping, to one-step scanning with optical probes and nuclear tracers – all in 3D. With ultra-high image resolutions and one-to-one translation from basic optical to clinical-ready nuclear diagnostic and targeted radiotherapy applications. Click here for more information.
Unmatched optical imaging versatility in
Bioluminescence, fluorescence, or Cherenkov imaging, MILabs optical imaging meets all your 2D imaging needs, for up to ten mice simultaneously. Add X-ray CT, and you can expand your applications to deep tissue imaging with 3D optical tomography. And when you need clinical-ready nuclear diagnostic and theranostic data, including targeted alpha therapy (TAT), just add in-line PET & SPECT. It’s that powerful and easy. Click here for more.
hexa-modal imaging of tumor necrosis
In a recent publication in Cancers (Feb. 2022), the research group of C. Löwik at Erasmus University searched for the best tracer for early detection of therapy-induced tumor necrosis. To Prof. Löwik’s knowledge, “this is the first time tumor necrosis is visualized by five in vivo imaging modalities in a single imaging session on the same animal (PET/SPECT/CT, FLI, and BLI)” Read more.
Job openings: be part of MILabs’ accelerating growth
MILabs seeks talented individuals to further scale-up its organization.